SEC Form 4 · accession 0001159036-26-000119
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Helen Torley
Officer — PRESIDENT AND CEO · Director
Period of report
Sep 9, 2026
Accepted (ET)
Sep 11, 2026 · 8:35 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001159036
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 9, 2026 | M | 20,000 | $18.41 | A | 787,780 | D | |
| Common StockF2 | Sep 9, 2026 | S | 13,304 | $107.222 | D | 774,476 | D | |
| Common StockF3 | Sep 9, 2026 | S | 6,596 | $107.821 | D | 767,880 | D | |
| Common Stock | Sep 9, 2026 | S | 100 | $108.67 | D | 767,780 | D | |
| Common Stock | Sep 10, 2026 | M | 20,000 | $18.41 | A | 787,780 | D | |
| Common StockF4 | Sep 10, 2026 | S | 14,588 | $107.012 | D | 773,192 | D | |
| Common StockF5 | Sep 10, 2026 | S | 5,412 | $107.581 | D | 767,780 | D | |
| Common Stock | Sep 11, 2026 | M | 20,000 | $18.41 | A | 787,780 | D | |
| Common StockF6 | Sep 11, 2026 | S | 15,492 | $107.154 | D | 772,288 | D | |
| Common StockF7 | Sep 11, 2026 | S | 4,508 | $107.548 | D | 767,780 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF8 | $18.41 | Sep 9, 2026 | M | 20,000 | D | — | Feb 14, 2028 | Common Stock | 20,000 | 121,552 | D |
| Option to Purchase Common StockF8 | $18.41 | Sep 10, 2026 | M | 20,000 | D | — | Feb 14, 2028 | Common Stock | 20,000 | 101,552 | D |
| Option to Purchase Common StockF8 | $18.41 | Sep 11, 2026 | M | 20,000 | D | — | Feb 14, 2028 | Common Stock | 20,000 | 81,552 | D |
Explanation of responses
- F1The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028.
- F2Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.640 to $107.632. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.640 to $108.290. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F4Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.360 to $107.350 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range
- F5Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.360 to $107.820 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range
- F6Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.400 to $107.390. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F7Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.400 to $107.960. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F8Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018.